23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Aurinia Pharmaceuticals Inc. › 2025-2026

Aurinia Pharmaceuticals Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Aurinia Pharmaceuticals Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Reported items
  • 261Asset managers, any item
  • 1,481Fund votes
  • June 3, 2026Meeting date

Results at a glance

Meeting of June 3, 2026: 7 items on Aurinia Pharmaceuticals Inc.’s Form 8-K, filed June 4, 2026: 2 approved · 5 passed (calculated).

Dissent

Notable dissent: 2 directors (13.5%, 13.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13D, 10.0%, as of June 4, 2026)

Explore Aurinia Pharmaceuticals Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Aurinia Pharmaceuticals Inc.

These tallies are Aurinia Pharmaceuticals Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Aurinia Pharmaceuticals Inc. — official shareholder meeting results, meeting held June 3, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Kevin Tang 68,889,411---- 2,434,09016,049,984 97%Passed (calculated)—
Elect Director: Jeffrey Bailey 67,990,723---- 3,332,77816,049,984 95%Passed (calculated)—
Elect Director: Kathy Goetz 68,840,807---- 2,482,69416,049,984 97%Passed (calculated)—
Elect Director: Craig Johnson 61,694,786---- 9,628,71516,049,984 86%Passed (calculated)—
Elect Director: Tina S. Nova 61,972,942---- 9,350,56016,049,983 87%Passed (calculated)—
Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Corporation's independent registered public accounting firm until the annual general meeting of shar 77,785,132---- 9,488,3503 89%Approved—
Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution regarding the Corporation's executive compensation. 66,398,9714,315,143609,384 --16,049,987 94%Approved—

Source: Aurinia Pharmaceuticals Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Aurinia Pharmaceuticals Inc. 2025-2026 meeting

261 asset managers disclosed a vote on at least one Aurinia Pharmaceuticals Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Aurinia Pharmaceuticals Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Kevin Tang

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 68,889,411WITHHELD: 2,434,090

Prior year: 85.9% for (May 15, 2025 meeting) ▲ 10.7 pts

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Election of Directors: Kevin Tang

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Kevin Tang”): 68,889,411 for, 2,434,090 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Aurinia Pharmaceuticals Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “To elect the following five director nominees presented by the Board: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova, Ph.D. Jeffrey Bailey” (9 managers, 4,896,599 for); “To elect the following five director nominees presented by the Board: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova, Ph.D. Kathy Goetz” (9 managers, 4,896,599 for); “To elect the following five director nominees presented by the Board: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova, Ph.D. Kevin Tang” (9 managers, 4,896,599 for); “To elect the following five director nominees presented by the Board: Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova, Ph.D. Tina S. Nova, Ph.D.” (9 managers, 4,896,599 for).

The 64 asset managers below reported 12,674,559 for, 19,562 withheld, 3 abstained.

FOR
FOR: 12,674,559ABSTAIN: 3WITHHOLD: 19,562
Largest asset managers voting on “Election of Directors: Kevin Tang” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock4,531,1550 00For
Fidelity1,775,8140 00For
Vanguard1,262,8860 30For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
QUANTITATIVE MASTER SERIES LLC199,2200 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
HUSSMAN INVESTMENT TRUST140,0000 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco100,5450 00For
DIAMOND HILL FUNDS92,2120 00For
Prudential/PGIM89,6000 00For
DWS85,0260 00For
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Craig Johnson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%
FOR: 61,694,786WITHHELD: 9,628,715

Prior year: 80.2% for (May 15, 2025 meeting) ▲ 6.3 pts

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Craig Johnson

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Craig Johnson”): 61,694,786 for, 9,628,715 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 7,786,782 for, 10,732 withheld, 12 abstained.

FOR
FOR: 7,786,782ABSTAIN: 12WITHHOLD: 10,732
Largest asset managers voting on “Election of Directors: Craig Johnson” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,775,8140 00For
Vanguard1,261,9790 12899For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
HUSSMAN INVESTMENT TRUST140,0000 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco100,5450 00For
Prudential/PGIM89,6000 00For
DWS85,0260 00For
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For
Nationwide56,4820 00For
PACE SELECT ADVISORS TRUST54,9620 00For
FundVantage Trust54,6250 00For

Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).

Elect Director: Jeffrey Bailey

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 67,990,723WITHHELD: 3,332,778
Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Jeffrey A. Bailey

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Jeffrey Bailey”): 67,990,723 for, 3,332,778 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 7,777,061 for, 20,461 withheld, 4 abstained.

FOR
FOR: 7,777,061ABSTAIN: 4WITHHOLD: 20,461
Largest asset managers voting on “Election of Directors: Jeffrey A. Bailey” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,775,8140 00For
Vanguard1,261,9870 4899For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
HUSSMAN INVESTMENT TRUST140,0000 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco100,5450 00For
Prudential/PGIM89,6000 00For
DWS85,0260 00For
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For
Nationwide56,4820 00For
PACE SELECT ADVISORS TRUST54,9620 00For
FundVantage Trust54,6250 00For

Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).

Elect Director: Kathy Goetz

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 68,840,807WITHHELD: 2,482,694

Prior year: 80.4% for (May 15, 2025 meeting) ▲ 16.1 pts

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Kathy Goetz

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Kathy Goetz”): 68,840,807 for, 2,482,694 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 7,777,960 for, 19,562 withheld, 3 abstained.

FOR
FOR: 7,777,960ABSTAIN: 3WITHHOLD: 19,562
Largest asset managers voting on “Election of Directors: Kathy Goetz” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,775,8140 00For
Vanguard1,262,8860 30For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
HUSSMAN INVESTMENT TRUST140,0000 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco100,5450 00For
Prudential/PGIM89,6000 00For
DWS85,0260 00For
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For
Nationwide56,4820 00For
PACE SELECT ADVISORS TRUST54,9620 00For
FundVantage Trust54,6250 00For

Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).

Elect Director: Tina S. Nova

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 61,972,942WITHHELD: 9,350,560

Prior year: 79.3% for (May 15, 2025 meeting) ▲ 7.6 pts

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Tina S. Nova

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Tina S. Nova”): 61,972,942 for, 9,350,560 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 7,777,951 for, 19,562 withheld, 12 abstained.

FOR
FOR: 7,777,951ABSTAIN: 12WITHHOLD: 19,562
Largest asset managers voting on “Election of Directors: Tina S. Nova” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,775,8140 00For
Vanguard1,262,8770 120For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
HUSSMAN INVESTMENT TRUST140,0000 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco100,5450 00For
Prudential/PGIM89,6000 00For
DWS85,0260 00For
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For
Nationwide56,4820 00For
PACE SELECT ADVISORS TRUST54,9620 00For
FundVantage Trust54,6250 00For

Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).

Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 66,398,971AGAINST: 4,315,143

Prior year: 77.4% for (May 15, 2025 meeting) ▲ 16.5 pts

Details: description as filed, official tally, votes by 185 asset managers

Description as filed by funds: Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, the Company's executive compensation set forth in the Company's Proxy Statement/Circular.

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Proposal 3: Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution regarding the Corporation's executive compensation.”): 66,398,971 for, 4,315,143 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution regarding the Corporation's executive compensation.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Aurinia Pharmaceuticals Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (8 managers, 109,699 for, 308,247 against); “APPROVAL OF COMPENSATION OF EXECUTIVE OFFICERS” (4 managers, 12,467,145 for); “To approve on a non-binding advisory basis the Companys executive compensation set forth in the Companys Proxy Statement/Circular” (2 managers, 2,803 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 54 asset managers voting on “Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, the Company's execu” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,775,8140 00For
Vanguard1,262,8835 10For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco0100,545 00Against
Prudential/PGIM89,6000 00For
DWS85,0260 00For
HUSSMAN INVESTMENT TRUST00 83,0000Abstain
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For
Nationwide56,4820 00For
PACE SELECT ADVISORS TRUST54,9620 00For
FundVantage Trust54,6250 00For

Fund voting reports, all 54 managers: 7,546,497 for, 100,669 against, 92,834 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 146 asset managers voting on “Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, the Company's execu” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC3,969,8340 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2,408,1570 00For
State Street2,090,1190 00For
Two Sigma1,822,9910 00For
GEODE CAPITAL MANAGEMENT, LLC1,541,8580 00For
Janus Henderson1,428,4240 00For
Renaissance850,2270 00For
LSV ASSET MANAGEMENT831,5470 00For
JUPITER ASSET MANAGEMENT LTD803,4190 00For
DE Shaw713,7890 00For
MARSHALL WACE, LLP691,4720 00For
Nuveen636,9480 00For
Prudential/PGIM583,9100 00For
Goldman Sachs561,8160 00For
AQR479,3220 00For
Charles Schwab454,1300 00For
American Century364,3780 00For
MELLON INVESTMENTS Corp350,7940 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM0350,562 00Against
Fidelity347,9290 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND275,3000 00For
Vanguard233,7750 00For
ClariVest Asset Management LLC213,9420 00For
Hillsdale Investment Management Inc.209,9000 00For
UBS0204,194 00Against

Institutional-manager reports, all 146 managers: 25,079,933 for, 920,942 against, 7,001 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 66,398,971AGAINST: 4,315,143

Prior year: 77.4% for (May 15, 2025 meeting) ▲ 16.5 pts

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To approve on a non-binding advisory basis the Company's executive compensation set forth in this Proxy Statement/Circular (the "say-on-pay" vote).

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Proposal 3: Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution regarding the Corporation's executive compensation.”): 66,398,971 for, 4,315,143 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Based upon the following votes, the shareholders approved, on a non-binding advisory basis, a "say on pay" resolution regarding the Corporation's executive compensation.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 8 asset managers voting on “To approve on a non-binding advisory basis the Company's executive compensation set forth in this Proxy Statem” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock4,531,1550 00For
QUANTITATIVE MASTER SERIES LLC199,2200 00For
DIAMOND HILL FUNDS92,2120 00For
John Hancock30,8650 00For
Bridge Builder Trust22,9490 00For
MASTER INVESTMENT PORTFOLIO12,7110 00For
NORTHERN LIGHTS FUND TRUST II4,2230 00For
WILSHIRE MUTUAL FUNDS INC3,2640 00For

Fund voting reports, all 8 managers: 4,896,599 for.

Institutional-manager reports: 58 asset managers voting on “To approve on a non-binding advisory basis the Company's executive compensation set forth in this Proxy Statem” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock2,504,4722,870 00For
Northern Trust693,6960 00For
JACOBS LEVY EQUITY MANAGEMENT, INC608,3180 00For
Goldman Sachs322,9860 00For
O'SHAUGHNESSY ASSET MANAGEMENT, LLC244,2920 00For
PNC BANK, NATIONAL ASSOCIATION236,6880 00For
WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC234,6390 00For
ROCKEFELLER FINANCIAL LLC81,2440 00For
Capital Investment Advisors, LLC33,7500 00For
Acropolis Investment Management, LLC19,6570 00For
Corient Private Wealth LP12,6220 00For
ENVESTNET ASSET MANAGEMENT INC11,3670 00For
Ensign Peak Advisors, Inc10,0850 00For
GRIMES & Co WEALTH MANAGEMENT, LLC9,8300 00For
US BANK NATIONAL ASSOCIATION8,8200 00For
OPPENHEIMER & CO INC8,4200 00For
First Bank & Trust6,5360 00For
Focus Partners Wealth6,0000 00For
Cerity Partners LLC3,4520 00For
SCOTIA CAPITAL INC.2,6060 00For
Soltis Investment Advisors LLC2,5000 00For
Savant Capital, LLC2,0010 00For
D.A. DAVIDSON & CO.2,0000 00For
SALEM INVESTMENT COUNSELORS INC1,9000 00For
CASTLEKEEP INVESTMENT ADVISORS LLC1,7780 00For

Institutional-manager reports, all 58 managers: 5,088,170 for, 2,870 against, 442 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

89% Approved · of votes cast

FOR 89%
FOR: 77,785,132WITHHELD: 9,488,350
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Appointment of Auditors To approve the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Company's independent registered public accounting firm until the close of the 2027 annual general meeting of shareholders or until a successor is appointed.

Aurinia Pharmaceuticals Inc.’s own tally for this item (“Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Corporation's independent registered public accounting firm ”): 77,785,132 for, 9,488,350 withheld — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Corporation's independent registered public accounting firm until the annual general meeting of shareholders to be held in 2027 or until a …”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 12,626,381 for, 10,732 withheld, 12 abstained.

FOR
FOR: 12,626,381ABSTAIN: 12WITHHOLD: 10,732
Largest asset managers voting on “Appointment of Auditors To approve the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accou” at Aurinia Pharmaceuticals Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock4,531,1550 00For
Fidelity1,775,8140 00For
Vanguard1,261,9790 12899For
Janus Detroit Street Trust701,4850 00For
TIAA613,7150 00For
Charles Schwab454,1300 00For
American Century361,1310 00For
State Street277,5070 00For
Equitable255,0180 00For
QUANTITATIVE MASTER SERIES LLC199,2200 00For
JPMorgan185,3990 00For
Goldman Sachs159,4310 00For
Lincoln Financial155,9100 00For
Principal Exchange-Traded Funds116,1800 00For
Invesco100,5450 00For
DIAMOND HILL FUNDS92,2120 00For
Prudential/PGIM89,6000 00For
DWS85,0260 00For
HUSSMAN INVESTMENT TRUST83,0000 00For
Northern Trust78,9010 00For
AIG/SunAmerica73,9090 00For
Federated Hermes66,3380 00For
TARGET PORTFOLIO TRUST62,0000 00For
ETFis Series Trust I57,3860 00For
Global X56,4930 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Largest Aurinia Pharmaceuticals Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 130,771,000 shares outstanding at the time of that meeting.

Fund voting reports: top Aurinia Pharmaceuticals Inc. shareholders by shares voted on “Appointment of Auditors To approve the appointment of PricewaterhouseCoopers LLP, Chartered…”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 3.46%
2Fidelity 1.36%
3Vanguard 0.97%
4Janus Detroit Street Trust 0.54%
5TIAA 0.47%
6Charles Schwab 0.35%
7American Century 0.28%
8State Street 0.21%
9Equitable 0.20%
10QUANTITATIVE MASTER SERIES LLC 0.15%
Institutional-manager reports: top Aurinia Pharmaceuticals Inc. shareholders by shares voted on “Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, the…”, 2025-2026
#Asset manager % of shares outstanding
1NEA Management Company, LLC 3.04%
2ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.84%
3State Street 1.60%
4Two Sigma 1.39%
5GEODE CAPITAL MANAGEMENT, LLC 1.18%
6Janus Henderson 1.09%
7Renaissance 0.65%
8LSV ASSET MANAGEMENT 0.64%
9JUPITER ASSET MANAGEMENT LTD 0.61%
10DE Shaw 0.55%

Reported Aurinia Pharmaceuticals Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Aurinia Pharmaceuticals Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock7,845,521 6.00%Form 13F, quarter ended March 31, 2026
Chin Kyu Huh5,911,237 4.52%Schedule 13D, filed August 26, 2026
Two Sigma3,428,705 2.62%Form 13F, quarter ended March 31, 2026
State Street2,527,099 1.93%Form 13F, quarter ended March 31, 2026
Morgan Stanley2,216,915 1.70%Form 13F, quarter ended March 31, 2026
Renaissance Technologies1,663,835 1.27%Form 13F, quarter ended March 31, 2026
D.E. Shaw1,572,983 1.20%Form 13F, quarter ended March 31, 2026
Geode Capital1,536,009 1.17%Form 13F, quarter ended March 31, 2026
Vanguard Group1,449,884 1.11%Form 13F, quarter ended March 31, 2026
Goldman Sachs1,433,508 1.10%Form 13F, quarter ended March 31, 2026

Percentages above are of 130,771,000 shares outstanding, as reported by Aurinia Pharmaceuticals Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Aurinia Pharmaceuticals Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 261 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,481 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, the… — Aurinia Pharmaceuticals Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Aurinia Pharmaceuticals Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aurinia Pharmaceuticals Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Aurinia Pharmaceuticals Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Aurinia Pharmaceuticals (AUPH) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aurinia-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.